Therapeutic Uses of Cholinesterase Inhibitors in Neurodegenerative Diseases

作者: Randall L. Woltjer , Dejan Milatovic

DOI: 10.1016/B978-012088523-7/50004-1

关键词:

摘要: Publisher Summary The chapter describes the rationale for therapies in Alzheimer's disease (AD), aspects of their application to clinical disease, and what is learned from effects drugs neurodegenerative disease. Effective preventive therapeutic strategies AD other age-related diseases are most pressing need modern neurological practice. multifactorial nature etiology sporadic seems imply a likelihood that effective treatment will target several or many these processes. Indeed, models progression invoke self-reinforcing cycles cerebral damage may be checked part at any one number steps, but best approached by multiple pathogenesis. Definitive experimental evidence role ACh pathogenesis human prove elusive, perhaps unambiguously manifest only context cotreatments with AChEIs agents symptomatic alone dictate they remain important treatments AD.

参考文章(105)
Richard Hartman, Yves Agid, Ravi Anand, Michael Rösler, Peter Dal-Bianco, Ana Cicin-Sain, Hannes B Stähelin, Marguirguis Gharabawi, Serge Gauthier, Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. ,vol. 318, pp. 633- 640 ,(1999) , 10.1136/BMJ.318.7184.633
ChristineM. Smith, Michael Swash, Physostigmine in Alzheimer's disease. The Lancet. ,vol. 313, pp. 42- 42 ,(1979) , 10.1016/S0140-6736(79)90479-3
Rachel Haring, Abraham Fisher, Daniele Marciano, Zipora Pittel, Yoel Kloog, Avi Zuckerman, Nomi Eshhar, Eliahu Heldman, Mitogen-Activated Protein Kinase-Dependent and Protein Kinase C-Dependent Pathways Link the m1 Muscarinic Receptor to β-Amyloid Precursor Protein Secretion Journal of Neurochemistry. ,vol. 71, pp. 2094- 2103 ,(2002) , 10.1046/J.1471-4159.1998.71052094.X
Jeffrey L. Cummings, Carla Back, The Cholinergic Hypothesis of Neuropsychiatric Symptoms in Alzheimer's Disease The American Journal of Geriatric Psychiatry. ,vol. 6, pp. S64- S78 ,(1998) , 10.1097/00019442-199821001-00009
Barry Reisberg, Steven H. Ferris, Emma Shulman, Gertrude Steinberg, Catherine Buttinger, Elia Sinaiko, Jeffrey Borenstein, Moni J. De Leon, Jacob Cohen, Longitudinal course of normal aging and progressive dementia of the Alzheimer's type: a prospective study of 106 subjects over a 3.6 year mean interval. Progress in Neuro-psychopharmacology & Biological Psychiatry. ,vol. 10, pp. 571- 578 ,(1986) , 10.1016/0278-5846(86)90026-6
R. Bartus, R. Dean, B Beer, A. Lippa, The cholinergic hypothesis of geriatric memory dysfunction Science. ,vol. 217, pp. 408- 414 ,(1982) , 10.1126/SCIENCE.7046051
Timo Erkinjuntti, Gustavo Román, Serge Gauthier, Treatment of vascular dementia—evidence from clinical trials with cholinesterase inhibitors Journal of the Neurological Sciences. ,vol. 226, pp. 63- 66 ,(2004) , 10.1016/J.JNS.2004.09.018
Christine M. Smith, Michael Swash, Possible biochemical basis of memory disorder in Alzheimer disease Annals of Neurology. ,vol. 3, pp. 471- 473 ,(1978) , 10.1002/ANA.410030602
O. V. Forlenza, J. M. Spink, R. Dayanandan, B. H. Anderton, O. F. Olesen, S. Lovestone, Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons. Journal of Neural Transmission. ,vol. 107, pp. 1201- 1212 ,(2000) , 10.1007/S007020070034
Lorna Piazzi, Angela Rampa, Alessandra Bisi, Silvia Gobbi, Federica Belluti, Andrea Cavalli, Manuela Bartolini, Vincenza Andrisano, Piero Valenti, Maurizio Recanatini, 3-(4-{[Benzyl(methyl)amino]methyl}phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) Inhibits Both Acetylcholinesterase and Acetylcholinesterase-Induced β-Amyloid Aggregation: A Dual Function Lead for Alzheimer's Disease Therapy§ Journal of Medicinal Chemistry. ,vol. 46, pp. 2279- 2282 ,(2003) , 10.1021/JM0340602